Arena Pharma (ARNA) Commences APD811 Phase 1
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) has initiated dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).
This randomized, double-blind and placebo-controlled dose titration trial is planned to enroll up to 30 healthy adult volunteers, and will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811 and the optimal titration schedule. Arena previously evaluated single-ascending doses of APD811 in the initial Phase 1 clinical trial.
This randomized, double-blind and placebo-controlled dose titration trial is planned to enroll up to 30 healthy adult volunteers, and will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811 and the optimal titration schedule. Arena previously evaluated single-ascending doses of APD811 in the initial Phase 1 clinical trial.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
- Leggett & Platt shareholders approve merger with Somnigroup
- Quanome Technologies forms quantum advisory council and network
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
